Moxifloxacina Vioser (Moxifloxacin Hydrochloride)

Moxifloxacin is indicated for several serious bacterial infections affecting the respiratory, sinus, skin, intra‑abdominal and bronchial systems.

• Community‑acquired bacterial pneumonia: effective treatment of infection caused by susceptible organisms.
• Acute bacterial sinusitis: eradicates the causative pathogens and relieves sinus inflammation.
• Complicated skin and skin‑structure infections: clears infection in deep or extensive skin lesions.
• Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic bacteria.
• Acute bacterial exacerbations of chronic bronchitis: reduces bacterial load and improves lung function.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death. This bactericidal activity is broad‑spectrum against Gram‑positive, Gram‑negative and atypical organisms.

Adverse reactions may vary from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, occasionally leading to dehydration.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: erythematous skin eruption.
• Injection site reactions: pain, erythema, or swelling at the infusion site.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: risk of ventricular arrhythmias.
• Clostridioides difficile infection: severe colitis after antibiotic exposure.
• Severe allergic reactions: anaphylaxis, angioedema.
• Hepatic failure: rare but potentially life‑threatening liver injury.
• Seizures: especially in patients with pre‑existing CNS disorders.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

• Renal impairment: adjust dose or monitor renal function closely.
• Hepatic impairment: evaluate liver enzymes and adjust therapy if needed.
• History of tendon disorders: avoid use due to risk of tendon rupture.
• Concomitant QT‑prolonging drugs: monitor ECG and electrolytes.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: increased risk of cumulative toxicity.
• Concurrent use with QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antibacterial activity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may affect drug stability.
• Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.
• Corticosteroids: increased likelihood of tendon injury.